Matches in UGent Biblio for { <https://biblio.ugent.be/publication/329629#aggregation> ?p ?o. }
Showing items 1 to 38 of
38
with 100 items per page.
- aggregation classification "A1".
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation date "2005".
- aggregation format "application/pdf".
- aggregation hasFormat 329629.bibtex.
- aggregation hasFormat 329629.csv.
- aggregation hasFormat 329629.dc.
- aggregation hasFormat 329629.didl.
- aggregation hasFormat 329629.doc.
- aggregation hasFormat 329629.json.
- aggregation hasFormat 329629.mets.
- aggregation hasFormat 329629.mods.
- aggregation hasFormat 329629.rdf.
- aggregation hasFormat 329629.ris.
- aggregation hasFormat 329629.txt.
- aggregation hasFormat 329629.xls.
- aggregation hasFormat 329629.yaml.
- aggregation isPartOf urn:issn:0003-4967.
- aggregation language "eng".
- aggregation rights "I have transferred the copyright for this publication to the publisher".
- aggregation subject "Medicine and Health Sciences".
- aggregation title "Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis".
- aggregation abstract "Objectives: To analyse the effect of infliximab on IgM rheumatoid factor (RF) and anti-cyclic citrullinated peptide (CCP) antibodies, and determine whether baseline autoantibody titres (IgM RF and anti-CCP antibodies) are associated with changes in acute phase reactants. Patients and methods: 62 patients with refractory RA were treated with infliximab combined with methotrexate. At baseline and week 30, serum samples were tested for IgM RF by two agglutination assays, and for anti-CCP antibodies by an ELISA. Percentage change in C reactive protein (CRP) and erythrocyte sedimentation rate (ESR) was calculated. Results: At baseline and week 30 RF titres were reduced significantly during infliximab treatment (p < 0.001 and p = 0.038, respectively), whereas anti-CCP antibodies were unchanged (p = 0.240). Baseline IgM RF titres, but not anti-CCP antibodies, correlated inversely with changes in CRP and ESR during treatment. Patients with a marked decrease in acute phase reactants had lower IgM RF titres than those with a smaller decrease in CRP and ESR; no significant differences were found for anti-CCP antibodies. Conclusion: The differential effect of infliximab treatment on IgM RF and anti-CCP antibodies, and the different predictive value on changes in acute phase reactants during infliximab treatment support the existing evidence that RF and anti-CCP antibodies are independent autoantibody systems in RA.".
- aggregation authorList BK386745.
- aggregation endPage "302".
- aggregation issue "2".
- aggregation startPage "299".
- aggregation volume "64".
- aggregation aggregates 3037373.
- aggregation isDescribedBy 329629.
- aggregation similarTo ard.2004.023523.
- aggregation similarTo LU-329629.